Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ilaris in mutation-negative or very young severe CAPS patients
2014-001393-34Phase 4Terminated
- Sponsor
- UZ Leuven
- Start
- Apr 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of canakinumab in cryopyrin-associated periodic syndrome (CAPS), sponsored by UZ Leuven. Primary endpoint: Clinical and biological response. Started Apr 2014; status: terminated.
02
Drugs
canakinumab
03
Conditions
cryopyrin-associated periodic syndrome (CAPS)
Beyond the preview
Go deeper on 2014-001393-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001393-34.